US 11,999,709 B2
Processes for preparing oxathiazin-like compounds
Rolf W. Pfirrmann, Weggis (CH); Hanns Moehler, Maennedorf (CH); and Thomas Mueller, Wolhusen (CH)
Assigned to GEISTLICH PHARMA AG, Wolhusen (CH)
Filed by GEISTLICH PHARMA AG, Wolhusen (CH)
Filed on Jan. 9, 2023, as Appl. No. 18/151,569.
Application 16/538,344 is a division of application No. 15/535,266, granted, now 10,392,355, issued on Aug. 27, 2019, previously published as PCT/IB2015/059741, filed on Dec. 17, 2015.
Application 18/151,569 is a continuation of application No. 17/150,359, filed on Jan. 15, 2021, granted, now 11,591,302.
Application 17/150,359 is a continuation in part of application No. 16/538,344, filed on Aug. 12, 2019, granted, now 10,968,190, issued on Apr. 6, 2021.
Claims priority of provisional application 62/094,580, filed on Dec. 19, 2014.
Prior Publication US 2023/0159477 A1, May 25, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 291/06 (2006.01); A61P 35/00 (2006.01); C07D 419/06 (2006.01)
CPC C07D 291/06 (2013.01) [A61P 35/00 (2018.01); C07D 419/06 (2013.01)] 20 Claims
 
1. A method of reducing or inhibiting cancer cell migration in a subject having a pancreatic cancer, an ovarian cancer, or a squamous cell carcinoma comprising administering an effective amount of a compound of formula I

OG Complex Work Unit Chemistry
wherein R is H, an alkyl, or benzyl, to the subject.